HealthCap

Oncorena AB develops drugs for cancer. It offers Oncorena that provides pharmacological treatment for metastasing clear cell renal cancer. The company is based in Göteborg, Sweden.

Elsa Science AB, founded in 2017 and based in Stockholm, Sweden, operates a digital health platform focused on rheumatoid arthritis. The company empowers patients to take an active role in their healthcare by providing tools that facilitate personal research into their condition. Through its application, users can monitor symptoms, diet, and lifestyle factors, gaining insights into how these elements influence their disease activity. Elsa collaborates with the Riskminder foundation and scientific studies at Karolinska Institutet to deliver reliable data and research findings. By enabling patients to track their responses to medications and overall health status, Elsa supports healthcare professionals in managing chronic diseases more effectively, improving treatment personalization and proactive care.

Doctrin AB is a healthcare technology company based in Stockholm, Sweden, that offers a cloud-based platform aimed at helping healthcare providers digitize the patient journey. Founded in 2016, the platform facilitates information gathering, decision support, and documentation services, effectively simulating the way doctors conduct patient interviews. By automating and simplifying various aspects of patient visits, Doctrin enables healthcare professionals to enhance their efficiency and improve patient outcomes. The platform serves as a comprehensive tool for meeting, guiding, treating, and following up with patients, thereby contributing to the modernization and effectiveness of healthcare delivery.

Doctrin AB is a healthcare technology company based in Stockholm, Sweden, that offers a cloud-based platform aimed at helping healthcare providers digitize the patient journey. Founded in 2016, the platform facilitates information gathering, decision support, and documentation services, effectively simulating the way doctors conduct patient interviews. By automating and simplifying various aspects of patient visits, Doctrin enables healthcare professionals to enhance their efficiency and improve patient outcomes. The platform serves as a comprehensive tool for meeting, guiding, treating, and following up with patients, thereby contributing to the modernization and effectiveness of healthcare delivery.

Aprea Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing cancer therapeutics that target the mutant p53 tumor suppressor protein. The lead product candidate, APR-246, is a first-in-class small molecule p53 reactivator currently in late-stage clinical development for hematologic malignancies, specifically myelodysplastic syndromes and acute myeloid leukemia. Founded in 2006 and headquartered in Boston, Massachusetts, Aprea aims to address significant unmet medical needs in cancer treatment through innovative therapies. The company is primarily backed by KDev Investments AB and other stakeholders, including Östersjöstiftelsen and Praktikerinvest, reflecting a strong investment foundation for its research and development efforts.

Oncorena AB develops drugs for cancer. It offers Oncorena that provides pharmacological treatment for metastasing clear cell renal cancer. The company is based in Göteborg, Sweden.

Modus Therapeutics AB is a clinical-stage drug development company based in Stockholm, Sweden, focused on creating pharmaceutical therapies. Founded in 2011, the company is developing sevuparin, a novel drug aimed at treating sickle cell disease, a painful inherited blood disorder that affects millions worldwide. In addition to its primary focus on sickle cell disease, Modus Therapeutics is also exploring the potential of sevuparin for treating conditions associated with severe systemic inflammation, such as sepsis, endotoxemia, and severe malaria, as well as anemia related to chronic inflammation, including kidney diseases. Through its innovative approach, Modus Therapeutics aims to improve patient outcomes and reduce healthcare costs associated with these disorders.

Doctrin AB is a healthcare technology company based in Stockholm, Sweden, that offers a cloud-based platform aimed at helping healthcare providers digitize the patient journey. Founded in 2016, the platform facilitates information gathering, decision support, and documentation services, effectively simulating the way doctors conduct patient interviews. By automating and simplifying various aspects of patient visits, Doctrin enables healthcare professionals to enhance their efficiency and improve patient outcomes. The platform serves as a comprehensive tool for meeting, guiding, treating, and following up with patients, thereby contributing to the modernization and effectiveness of healthcare delivery.

BONESUPPORT is a medical technology company dedicated to the development of injectable osteoconductive biomaterials for the treatment of fragility fractures caused by osteoporosis, and bone voids or gaps caused by trauma, disease or related to surgical procedures. The company's mission is to restore health to enhance the quality of life for patients with bone disorders. BONESUPPORT was founded on 2000 and is headquartered in Lund, Sweden.

Aprea Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing cancer therapeutics that target the mutant p53 tumor suppressor protein. The lead product candidate, APR-246, is a first-in-class small molecule p53 reactivator currently in late-stage clinical development for hematologic malignancies, specifically myelodysplastic syndromes and acute myeloid leukemia. Founded in 2006 and headquartered in Boston, Massachusetts, Aprea aims to address significant unmet medical needs in cancer treatment through innovative therapies. The company is primarily backed by KDev Investments AB and other stakeholders, including Östersjöstiftelsen and Praktikerinvest, reflecting a strong investment foundation for its research and development efforts.

LTB4 is developing a naturally occurring molecule stimulating the innate immunity system to target diseases such as infections and cancer.

Glionova AB is a biopharmaceutical company based in Stockholm, Sweden, focused on developing therapies for challenging cancers. Founded in 2014, the company is working on GLN-1001, an orally bioavailable small molecule designed to selectively induce cell death in glioblastoma cells while sparing normal brain tissue. This innovative approach aims to improve treatment outcomes for patients suffering from glioblastoma, a common and aggressive form of primary brain tumor. In addition to its core product development, Glionova seeks to establish strategic partnerships with global pharmaceutical companies that specialize in oncology to enhance its market presence and advance its therapeutic offerings.

Wilson Therapeutics is a biopharmaceutical company located in Stockholm, Sweden, focusing on the development of innovative therapies for rare diseases, particularly Wilson Disease. The company’s primary product, Decuprate®, is being investigated as a new treatment option for this condition and is currently undergoing evaluation in a Phase II clinical study involving patients with Wilson Disease. By targeting copper-mediated disorders, Wilson Therapeutics aims to address unmet medical needs in this specialized area of healthcare.

BONESUPPORT is a medical technology company dedicated to the development of injectable osteoconductive biomaterials for the treatment of fragility fractures caused by osteoporosis, and bone voids or gaps caused by trauma, disease or related to surgical procedures. The company's mission is to restore health to enhance the quality of life for patients with bone disorders. BONESUPPORT was founded on 2000 and is headquartered in Lund, Sweden.

BONESUPPORT is a medical technology company dedicated to the development of injectable osteoconductive biomaterials for the treatment of fragility fractures caused by osteoporosis, and bone voids or gaps caused by trauma, disease or related to surgical procedures. The company's mission is to restore health to enhance the quality of life for patients with bone disorders. BONESUPPORT was founded on 2000 and is headquartered in Lund, Sweden.

Cardoz AB manufactures anti-inflammatory pharmaceuticals to combat heart and vascular disorders. The company was founded in 2006 and is based in Stockholm, Sweden.

OxThera AB is a biopharmaceutical company based in Stockholm, Sweden, with an additional location in Knoxville, Tennessee. Founded in 2005, it focuses on developing treatments for primary and secondary hyperoxaluria, a condition that can lead to kidney stones and impaired kidney function. The company's leading products include Oxabact, an oral formulation of live bacteria designed to enhance the elimination of oxalate produced in the body, and Oxazyme, a recombinant enzyme aimed at managing dietary oxalate and preventing kidney stone formation. Oxabact has received Orphan Drug designations in both Europe and the United States, underscoring its potential in treating primary hyperoxaluria. OxThera holds global patents for its innovative approaches using bacteria and enzymes to address hyperoxaluria, contributing to advancements in kidney disease management.

BONESUPPORT is a medical technology company dedicated to the development of injectable osteoconductive biomaterials for the treatment of fragility fractures caused by osteoporosis, and bone voids or gaps caused by trauma, disease or related to surgical procedures. The company's mission is to restore health to enhance the quality of life for patients with bone disorders. BONESUPPORT was founded on 2000 and is headquartered in Lund, Sweden.

Resistentia Pharmaceuticals, a biopharmaceutical company, develops immunotherapeutic products for allergic asthma and inflammatory disorders. It provides Immunoglobulin E for allergic reactions, including asthma, rhinitis, and dermatitis; and C5a for the treatment of inflammatory conditions, such as rheumatoid arthritis, asthma, and multiple sclerosis. Resistentia Pharmaceuticals AB was founded in 1998 and is based in Uppsala, Sweden.

OxThera AB is a biopharmaceutical company based in Stockholm, Sweden, with an additional location in Knoxville, Tennessee. Founded in 2005, it focuses on developing treatments for primary and secondary hyperoxaluria, a condition that can lead to kidney stones and impaired kidney function. The company's leading products include Oxabact, an oral formulation of live bacteria designed to enhance the elimination of oxalate produced in the body, and Oxazyme, a recombinant enzyme aimed at managing dietary oxalate and preventing kidney stone formation. Oxabact has received Orphan Drug designations in both Europe and the United States, underscoring its potential in treating primary hyperoxaluria. OxThera holds global patents for its innovative approaches using bacteria and enzymes to address hyperoxaluria, contributing to advancements in kidney disease management.

Biolipox is a research-intense pharmaceutical company that develops treatments for inflammatory diseases. This includes widespread diseases such as asthma, COPD, rhinitis, and inflammatory and rheumatic pain. The company offers its users with current arachidonic acid research. Arachidonic acid is an endogenous substance that plays a central role in the development of inflammatory diseases. It is an established research area that empowers several drugs such as Aspirin, Naproxen, and Singulair. Biolipox is a Sweden-based company that was founded in 2000 and the company was acquired by Orexo on November 23, 2007.

Orexo is a pharmaceutical company focused on developing specialized drugs and innovative treatments by leveraging known substances and proprietary technologies. The company operates primarily in the United States and Sweden, with a significant portion of its revenue stemming from its USA Pharma segment, which involves the commercialization of fully owned pharmaceuticals in the U.S. market. Orexo also explores Digital Therapeutics, offering evidence-based digital solutions that are currently in early development stages. Additionally, its headquarters in Uppsala, Sweden, oversees the research and development of new pharmaceutical products, contributing to Orexo's goal of delivering effective treatments at reduced costs and risks in a shorter timeframe.

Biolipox is a research-intense pharmaceutical company that develops treatments for inflammatory diseases. This includes widespread diseases such as asthma, COPD, rhinitis, and inflammatory and rheumatic pain. The company offers its users with current arachidonic acid research. Arachidonic acid is an endogenous substance that plays a central role in the development of inflammatory diseases. It is an established research area that empowers several drugs such as Aspirin, Naproxen, and Singulair. Biolipox is a Sweden-based company that was founded in 2000 and the company was acquired by Orexo on November 23, 2007.

Direct Conversion AB specializes in the research, development, manufacturing, and marketing of advanced X-ray imaging sensors that utilize photon counting and hybridized semiconductor technology. Its products cater to various sectors, including dental, medical, welding, food, security, and industrial applications. The company offers a range of photon counting products under the XCounter brand, including the XC-Hydra, XC-Thor, XC-TDI, and XC-Actaeon series. Additionally, it provides charge integrating detectors under the AJAT brand, featuring models such as SNAP 225 and ARISTO. Direct Conversion also develops cadmium telluride direct conversion detectors. Founded in 1997 and headquartered in Danderyd, Sweden, the company operates additional offices in London, Espoo, and Munich. In December 2016, it changed its name from XCounter AB to Direct Conversion AB and is currently a subsidiary of Varex Imaging Corporation.